1. Home
  2. HKIT vs AYTU Comparison

HKIT vs AYTU Comparison

Compare HKIT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

HOLD

Current Price

$2.84

Market Cap

28.3M

Sector

Technology

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.21

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
AYTU
Founded
1996
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3M
27.4M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
HKIT
AYTU
Price
$2.84
$2.21
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
37.5K
25.9K
Earning Date
04-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$0.03
$1.65
52 Week High
$8.80
$3.07

Technical Indicators

Market Signals
Indicator
HKIT
AYTU
Relative Strength Index (RSI) 46.70 51.48
Support Level $2.36 $2.21
Resistance Level $3.34 $2.32
Average True Range (ATR) 0.20 0.07
MACD -0.05 -0.01
Stochastic Oscillator 10.19 44.04

Price Performance

Historical Comparison
HKIT
AYTU

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: